Galmed Pharmaceuticals Ltd.(GLMD)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $2.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
GLMD Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Galmed Pharmaceuticals Ltd. (GLMD), a Healthcare sector company. GLMD is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $2.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of GLMD by reported 13-F value include CITADEL ADVISORS, XTX Topco Ltd, TWO SIGMA SECURITIES, based on the most recent SEC filings. GLMD trades on the Nasdaq exchange and files with the SEC under CIK 1595353. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GLMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Galmed Pharmaceuticals Ltd. directly from SEC EDGAR.
Net Income
Q4 2025
$-4.8M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
-37.1% YoYOperating Income
EPS (Diluted)
-70.4% YoYTotal Assets
+0.7% YoYOp. Cash Flow
-7.4% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0.00 |
| Net Income | $-10.3M -37.1% | $-7.5M -8.8% | $-6.9M +61.3% | $-17.9M +45.0% | $-32.5M -12.8% | $-28.8M |
| Operating Income | — | — | — | — | — | $-30.2M |
| EPS (Diluted) | $2.39 -70.4% | $8.08 -73.1% | $30.00 -76.5% | $127.80 +545.5% | $19.80 | — |
| Total Assets | $18.6M +0.7% | $18.5M +11.3% | $16.6M +0.4% | $16.6M -54.8% | $36.6M -30.1% | $52.4M |
| Operating Cash Flow | $-6.3M -7.4% | $-5.9M +4.2% | $-6.1M +66.8% | $-18.5M +43.8% | $-32.9M -25.1% | $-26.3M |
| Free Cash Flow | — | — | — | $-18.5M +43.8% | $-32.9M -25.0% | $-26.3M |
Get alerted when GLMD's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Galmed Pharmaceuticals Ltd. including:
Top Institutional Holders of GLMD
CITADEL ADVISORS LLC
$48.3K86,851 shXTX Topco Ltd
$8.4K15,015 shTWO SIGMA SECURITIES, LLC
$6.1K11,012 shSBI Securities Co., Ltd.
$37.0066 shMORGAN STANLEY
$31.0056 shWELLS FARGO & COMPANY/MN
$24.0043 shHRT FINANCIAL LP
$23.0042,090 shFederation des caisses Desjardins du Quebec
$8.0014 shOSAIC HOLDINGS, INC.
$2.005 shAllworth Financial LP
$2.002 sh
| Fund | Value | Shares |
|---|---|---|
| CITADEL ADVISORS LLC | $48.3K | 86,851 |
| XTX Topco Ltd | $8.4K | 15,015 |
| TWO SIGMA SECURITIES, LLC | $6.1K | 11,012 |
| SBI Securities Co., Ltd. | $37.00 | 66 |
| MORGAN STANLEY | $31.00 | 56 |
| WELLS FARGO & COMPANY/MN | $24.00 | 43 |
| HRT FINANCIAL LP | $23.00 | 42,090 |
| Federation des caisses Desjardins du Quebec | $8.00 | 14 |
| OSAIC HOLDINGS, INC. | $2.00 | 5 |
| Allworth Financial LP | $2.00 | 2 |
More Healthcare Companies
View all Healthcare →Put GLMD on your watchlist
Track score changes the day Galmed Pharmaceuticals Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is GLMD a good stock to buy?
13F Pro's AI-powered analysis of Galmed Pharmaceuticals Ltd. (GLMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GLMD are available on the GLMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. GLMD is classified as a small company.
Which hedge funds own GLMD?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GLMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Galmed Pharmaceuticals Ltd.'s investment landscape.